spironolactone has been researched along with Fibrosis in 158 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 9.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 9.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "These findings do not support the use of spironolactone in hypertrophic cardiomyopathy to improve left ventricular remodeling by mitigating myocardial fibrosis or altering clinical course." | 9.27 | Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. ( Chan, RH; Jaffe, IZ; Kapur, NK; Kerur, R; Maron, BJ; Maron, MS; McGraw, AP; Udelson, JE, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 9.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "Eplerenone is reported to reduce the development of atrial fibrillation (AF)." | 9.24 | Eplerenone might affect atrial fibrosis in patients with hypertension. ( Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T, 2017) |
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 9.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown." | 7.85 | Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling. ( Berenfeld, O; Ennis, SR; Guerrero-Serna, G; Jalife, J; Kaur, K; Ponce-Balbuena, D; Ramirez, RJ; Ramos-Mondragón, R; Salvador-Montañés, O; Takemoto, Y, 2017) |
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 7.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| "The purpose of the present study was to study the impacts of eplerenone (EPL), an antagonist of mineralocorticoid receptors (MR), on atrial fibrosis in a mouse model with selective fibrosis in the atrium, and to explore the possible mechanisms." | 7.83 | Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice. ( Chen, X; Du, L; Duan, S; Liu, X; Liu, Y; Wang, Q; Yi, Y; Zhang, W, 2016) |
| "MBG-induced vascular fibrosis is a likely target for spironolactone." | 7.81 | Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. ( Bagrov, AY; Bagrov, KA; Emelianov, IV; Fedorova, OV; Frolova, EV; Grigorova, YN; Juhasz, O; Konradi, AO; Lakatta, EG; Marshall, CA; Wei, W, 2015) |
| "Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats." | 7.81 | Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. ( Blotta, DA; Bonomo, C; Campos, DH; Cezar, MD; Cicogna, AC; Damatto, RL; Gomes, MJ; Lima, AR; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, SA; Pagan, LU; Rosa, CM, 2015) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 7.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| "Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease." | 7.80 | Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. ( Coelho-Filho, OR; Jerosch-Herold, M; Kwong, R; Mitchell, R; Moreno, H; Neilan, TG; Shah, RV, 2014) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 7.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 7.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| "Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration." | 7.79 | Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents." | 7.77 | Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011) |
| " To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)." | 7.74 | Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007) |
| "We investigated, whether the substrate for nitric oxide (NO) formation -L-arginine - and the aldosterone receptor antagonist - spironolactone - are able to reverse alterations of the left ventricle (LV) and aorta in N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension." | 7.74 | Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. ( Adamcova, M; Hulin, I; Janega, P; Krajcirovicova, K; Matuskova, J; Paulis, L; Pechanova, O; Pelouch, V; Potacova, A; Simko, F; Simko, J, 2008) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 7.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 7.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 7.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "We evaluated the role of aldosterone as a mediator of renal inflammation and fibrosis in a rat model of aldosterone/salt hypertension using the selective aldosterone blocker, eplerenone." | 7.72 | Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. ( Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| " Spironolactone (50 mg/kg/daily) or 1% dimethyl sulfoxide vehicle was administered by subcutaneous injection for 1 to 2 weeks, and renal fibrosis was assessed by measuring trichrome staining and type I collagen deposition in the kidney." | 7.72 | Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. ( Morgado, M; Palmer, LS; Trachtman, H; Valderrama, E; Weiser, AC, 2004) |
| " The present study was conducted to examine whether spironolactone, a mineralocorticoid receptor antagonist, alone or in combination with cilazapril, an angiotensin converting enzyme (ACE) inhibitor, ameliorates proteinuria and renal lesions in an immune-initiated progressive nephritis model." | 7.72 | Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. ( Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J, 2004) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 7.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 6.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Increased fibrosis was accompanied by myofibroblast and macrophage infiltration in the heart and the kidney." | 5.62 | The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. ( Leader, CJ; Walker, RJ; Wilkins, GT, 2021) |
| "The mechanisms underlying cardiorenal syndromes are complex and not fully understood; Fibrosis seems to be a primary driver of the diseases' pathophysiology." | 5.51 | Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats. ( Chen, L; Chen, X; Dong, T; Fan, X; Ge, W; Gong, Y; Hu, J; Zhou, H, 2019) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 5.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
| " Spironolactone dissolved in ddH2O was administered via gavage at a dosage of 20 mg·kg(-1)·day(-1)." | 5.42 | Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats. ( Ge, QF; Gu, DW; Li, GP; Li, HT; Zhao, H, 2015) |
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 5.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| " Treatment with spironolactone did not affect the biomarker of fibrosis Gal-3 in AF patients." | 5.41 | Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. ( Angelov, A; Bocheva, Y; Chervenkov, T; Kisheva, A; Yotov, Y, 2021) |
| "Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality." | 5.38 | Spironolactone and colitis: increased mortality in rodents and in humans. ( Gillespie, BW; Govani, SM; Higgins, PD; Johnson, LA; Joyce, JC; Waljee, AK, 2012) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 5.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| "Spironolactone treatment markedly suppressed osteopontin expression." | 5.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
| "Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy." | 5.35 | Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 5.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 5.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone." | 5.32 | Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 5.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 5.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "These findings do not support the use of spironolactone in hypertrophic cardiomyopathy to improve left ventricular remodeling by mitigating myocardial fibrosis or altering clinical course." | 5.27 | Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. ( Chan, RH; Jaffe, IZ; Kapur, NK; Kerur, R; Maron, BJ; Maron, MS; McGraw, AP; Udelson, JE, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 5.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "Eplerenone is reported to reduce the development of atrial fibrillation (AF)." | 5.24 | Eplerenone might affect atrial fibrosis in patients with hypertension. ( Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T, 2017) |
| "Patients with SRV treated with eplerenone showed an improvement of an altered baseline CTB profile suggesting that reduction of myocardial fibrosis might be a therapeutic target in these patients." | 5.17 | Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. ( Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M, 2013) |
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 5.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| "As myocardial fibrosis might be an important contributor to the association of obesity with left ventricular (LV) dysfunction and heart failure, we investigated the effects of spironolactone on LV function and serological fibrosis markers (procollagen type III N-terminal propeptide (PIIINP) and procollagen type I C-terminal propeptide (PICP)) in patients with obesity and abnormal LV performance." | 5.17 | Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. ( Kosmala, W; Marwick, TH; Mysiak, A; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2013) |
| "The purpose of this study was to identify the effects of spironolactone on left ventricular (LV) structure and function, and serological fibrosis markers in patients with metabolic syndrome (MS) taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.15 | A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. ( Kosmala, W; Marwick, TH; Mysiak, A; O'Moore-Sullivan, T; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2011) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " The effects of the mineralocorticoid receptor antagonist spironolactone on left ventricular (LV) function and chamber stiffness associated with myocardial fibrosis were investigated in mildly symptomatic patients with idiopathic dilated cardiomyopathy (DCM)." | 5.11 | Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. ( Amano, T; Asano, H; Ichihara, S; Iino, S; Isobe, S; Izawa, H; Kato, T; Murase, Y; Murohara, T; Nagata, K; Noda, A; Obata, K; Ohshima, S; Okumura, K; Yokota, M, 2005) |
| "We report the findings in 31 patients with stable chronic heart failure (CHF) who were treated with spironolactone (50-100 mg/day) or placebo in addition to diuretics and angiotensin converting enzyme (ACE) inhibition." | 5.08 | Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. ( Barr, CS; MacFadyen, RJ; Struthers, AD, 1997) |
| " Hyperaldosteronism due to klotho deficiency results in vascular calcification, which can be mitigated by spironolactone treatment." | 4.90 | Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. ( Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Kienreich, K; Kraigher-Krainer, E; März, W; Mrak, P; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Toplak, H; Verheyen, N, 2014) |
| "To identify the effects of diuretic agents on adverse cardiac remodeling in CHF, this study was carried out, where we have compared the effects of torasemide and spironolactone in a rat model of dilated cardiomyopathy induced by porcine cardiac myosin-mediated experimental autoimmune myocarditis." | 3.85 | Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy. ( Arumugam, S; Harima, M; Karuppagounder, V; Nakamura, M; Sone, H; Sreedhar, R; Suzuki, H; Watanabe, K, 2017) |
| "The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown." | 3.85 | Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling. ( Berenfeld, O; Ennis, SR; Guerrero-Serna, G; Jalife, J; Kaur, K; Ponce-Balbuena, D; Ramirez, RJ; Ramos-Mondragón, R; Salvador-Montañés, O; Takemoto, Y, 2017) |
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 3.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| "The purpose of the present study was to study the impacts of eplerenone (EPL), an antagonist of mineralocorticoid receptors (MR), on atrial fibrosis in a mouse model with selective fibrosis in the atrium, and to explore the possible mechanisms." | 3.83 | Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice. ( Chen, X; Du, L; Duan, S; Liu, X; Liu, Y; Wang, Q; Yi, Y; Zhang, W, 2016) |
| "Acute myocardial infarction was induced in 60 rats via left coronary artery ligation: 50 animals were randomized to be euthanized after 1, 2, 4, 12, or 24 weeks; 10 animals were treated with eplerenone (100 mg/kg/days) 7 days before the AMI until their euthanasia (4 weeks later); 8 additional animals underwent surgery without ligation (control)." | 3.83 | The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. ( Asensio-López, MC; Caballero, L; Fernández-Del Palacio, MJ; Gimeno-Blanes, JR; Lax, A; Navarro-Peñalver, M; Pascual-Figal, DA; Pérez-Martínez, MT; Sánchez-Más, J, 2016) |
| "1) the beneficial effect of aliskiren on SBP was enhanced by simultaneous administration of spironolactone; 2) echocardiographic studies showed that the left ventricle diameter (LVD), the left ventricle end diastolic volume (LVEDV) and the left ventricle posterior wall thickness (LVPW) were significantly reduced by the combination of both drugs when compared with aliskiren alone; 3) the ejection fraction was also increased; 4) histological studies indicated a greater decline in perivascular and interstitial fibrosis when both drugs were used; 5) the decrease of electrical remodeling of the left ventricle caused by aliskiren was further reduced by simultaneous administration of spironolactone; 6) the cardiac refractoriness increased by aliskiren was further incremented by spironolactone." | 3.81 | Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR(mRen2)27 rats. ( De Mello, WC, 2015) |
| "MBG-induced vascular fibrosis is a likely target for spironolactone." | 3.81 | Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. ( Bagrov, AY; Bagrov, KA; Emelianov, IV; Fedorova, OV; Frolova, EV; Grigorova, YN; Juhasz, O; Konradi, AO; Lakatta, EG; Marshall, CA; Wei, W, 2015) |
| "Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats." | 3.81 | Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. ( Blotta, DA; Bonomo, C; Campos, DH; Cezar, MD; Cicogna, AC; Damatto, RL; Gomes, MJ; Lima, AR; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, SA; Pagan, LU; Rosa, CM, 2015) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 3.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| "Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease." | 3.80 | Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. ( Coelho-Filho, OR; Jerosch-Herold, M; Kwong, R; Mitchell, R; Moreno, H; Neilan, TG; Shah, RV, 2014) |
| " We evaluated the efficacy of MR antagonism by spironolactone in two experimental PH models; mouse chronic hypoxia-induced PH (prevention model) and rat monocrotaline-induced PH (prevention and treatment models)." | 3.79 | Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. ( Fanburg, BL; Hill, NS; Jaffe, IZ; Preston, IR; Sagliani, KD; Warburton, RR, 2013) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 3.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 3.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| "Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration." | 3.79 | Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents." | 3.77 | Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011) |
| " We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice." | 3.76 | Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| " To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)." | 3.74 | Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007) |
| "We investigated, whether the substrate for nitric oxide (NO) formation -L-arginine - and the aldosterone receptor antagonist - spironolactone - are able to reverse alterations of the left ventricle (LV) and aorta in N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension." | 3.74 | Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. ( Adamcova, M; Hulin, I; Janega, P; Krajcirovicova, K; Matuskova, J; Paulis, L; Pechanova, O; Pelouch, V; Potacova, A; Simko, F; Simko, J, 2008) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 3.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| " Aldosterone itself has been shown to increase cardiovascular fibrosis, therefore, we studied the suppressive effects of eplerenone, a new aldosterone receptor antagonist, on neointimal hyperplasia after coronary stent implantation in swine." | 3.73 | Eplerenone suppresses neointimal formation after coronary stent implantation in swine. ( Iso, Y; Katagiri, T; Sato, T; Suzuki, H; Takeyama, Y; Wakabayashi, K, 2006) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 3.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 3.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "Long-term exposure of uninephrectomized rats to desoxycorticosterone acetate (DOCA)/salt induces cardiac fibrosis and hypertrophy through mineralocorticoid receptors (MRs)." | 3.72 | Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2003) |
| "We evaluated the role of aldosterone as a mediator of renal inflammation and fibrosis in a rat model of aldosterone/salt hypertension using the selective aldosterone blocker, eplerenone." | 3.72 | Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. ( Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| " Spironolactone (50 mg/kg/daily) or 1% dimethyl sulfoxide vehicle was administered by subcutaneous injection for 1 to 2 weeks, and renal fibrosis was assessed by measuring trichrome staining and type I collagen deposition in the kidney." | 3.72 | Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. ( Morgado, M; Palmer, LS; Trachtman, H; Valderrama, E; Weiser, AC, 2004) |
| "Streptozotocin-induced renal fibrosis, PAI-1 expression, TGF-beta1 expression, and macrophage infiltration occur via mineralocorticoid receptor, and spironolactone ameliorates renal fibrosis presumably via the inhibition of macrophage infiltration, PAI-1 expression, and TGF-beta1 expression in streptozotocin-induced early diabetic injury." | 3.72 | Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2004) |
| " The present study was conducted to examine whether spironolactone, a mineralocorticoid receptor antagonist, alone or in combination with cilazapril, an angiotensin converting enzyme (ACE) inhibitor, ameliorates proteinuria and renal lesions in an immune-initiated progressive nephritis model." | 3.72 | Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. ( Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J, 2004) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 3.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Myocardial fibrosis is one of the key mechanisms and aldosterone is a key mediator of myocardial fibrosis." | 2.78 | Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy. ( Heritier, S; Leung, DY; Leung, M; Mihailidou, AS; Wong, VW, 2013) |
| "Spironolactone has been shown to exert positive effects in human patients with heart failure; however, the mechanisms and effects in human atrial fibrosis and AF remain undetermined." | 2.46 | Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. ( Lyon, RC; Pellman, J; Sheikh, F, 2010) |
| "Aldosterone has direct effects on the vasculature and has been associated with vascular smooth muscle cell hypertrophy, endothelial dysfunction, cardiac fibrosis, proteinuria, and renal vascular injury." | 2.42 | Aldosterone: a risk factor for vascular disease. ( Fritsch Neves, M; Schiffrin, EL, 2003) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 2.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Heart failure is the main causes of morbidity and mortality." | 1.91 | Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy. ( Alcalai, R; Arad, M; Guetta, T; Hochhauser, E; Kornowski, R; Ofek, E; Petrover, Z; Seidman, CE; Seidman, J; Yadin, D, 2023) |
| "Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide." | 1.72 | Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. ( Chang, WT; Chen, CY; Chen, ZC; Lin, YW; Liu, PY; Luo, CY; Shih, JY; Wu, CC, 2022) |
| "Increased fibrosis was accompanied by myofibroblast and macrophage infiltration in the heart and the kidney." | 1.62 | The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. ( Leader, CJ; Walker, RJ; Wilkins, GT, 2021) |
| "The mechanisms underlying cardiorenal syndromes are complex and not fully understood; Fibrosis seems to be a primary driver of the diseases' pathophysiology." | 1.51 | Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats. ( Chen, L; Chen, X; Dong, T; Fan, X; Ge, W; Gong, Y; Hu, J; Zhou, H, 2019) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 1.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
| "Spironolactone treatment blocked the fibrogenic response of HIOs to TGFβ." | 1.42 | Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. ( Higgins, PD; Huang, S; Johnson, LA; Rodansky, ES; Spence, JR, 2015) |
| "In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels." | 1.42 | Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. ( Cachofeiro, V; Calvier, L; Fernández-Celis, A; Jaisser, F; Jurado-López, R; López-Andrés, N; Martínez-Martínez, E; Rossignol, P; Rossoni, LV; Rousseau, E; Zannad, F, 2015) |
| " Spironolactone dissolved in ddH2O was administered via gavage at a dosage of 20 mg·kg(-1)·day(-1)." | 1.42 | Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats. ( Ge, QF; Gu, DW; Li, GP; Li, HT; Zhao, H, 2015) |
| "Corticosterone or vehicle was injected twice daily in rats from 8 to 12 weeks of age." | 1.39 | Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Hattori, T; Iwase, E; Miyachi, M; Murase, T; Murohara, T; Nagata, K; Ohtake, M; Takahashi, K; Tsuboi, K, 2013) |
| "Severe muscle fibrosis is the endpoint of many chronic myopathies." | 1.39 | Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents. ( Gibertini, S; Mantegazza, R; Mora, M; Savadori, P; Zanotti, S, 2013) |
| "Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality." | 1.38 | Spironolactone and colitis: increased mortality in rodents and in humans. ( Gillespie, BW; Govani, SM; Higgins, PD; Johnson, LA; Joyce, JC; Waljee, AK, 2012) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 1.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| "Hyperaldosteronism combined with hypertension favored the macrophage infiltration (CD68(+) cells) in heart, and enhanced the mRNA level of monocyte chemoattractant protein 1, osteopontin, and galectin 3." | 1.38 | Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. ( Azibani, F; Benard, L; Carrier, L; Chatziantoniou, C; Delcayre, C; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Tournoux, F, 2012) |
| "Treatment with spironolactone was evaluated to prove mineralocorticoid mediation." | 1.37 | Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. ( Ballesteros, S; Cachofeiro, V; de las Heras, N; Delgado, C; Hintze, T; Lahera, V; Martín-Fernández, B; Miana, M; Song, S, 2011) |
| "Hypertension is well known to increase atrial fibrillation (AF) and the development of AF is associated with atrial chamber remodeling." | 1.37 | Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. ( Aizawa, Y; Chinushi, M; Ding, L; Hanawa, H; Hoyano, M; Ito, M; Kimura, S; Kodama, M; Obata, H; Tomita, M, 2011) |
| "Spironolactone treatment reversed all the above effects." | 1.37 | A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Spironolactone treatment markedly suppressed osteopontin expression." | 1.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
| "Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy." | 1.35 | Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008) |
| "Aldosterone plays a crucial role in renal fibrosis by inducing mesangial cell proliferation and promoting collagen synthesis in renal fibroblasts." | 1.35 | Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. ( Liu, A; Liu, X; Xu, G, 2008) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 1.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "High salt diet causes cardiac hypertrophy and fibrosis and increases cardiac aldosterone, while decreasing plasma aldosterone." | 1.32 | Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. ( Lal, A; Leenen, FH; Veinot, JP, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "In 23 patients with cirrhotic ascites, the daily administered initial dosage of 100 mg of spironolactone was increased by 100 mg/day at intervals of 5 days until either diuresis commenced or TTKG fell below 3." | 1.31 | Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. ( Han, JS; Kim, CY; Kim, KA; Lee, HS; Lim, YS; Yoon, JH, 2002) |
| "Aldosterone promotes nephrosclerosis in several rat models, whereas aldosterone receptor antagonism blunts the effect of activation of the renin-angiotensin-aldosterone system (RAAS) on nephrosclerosis, independent of effects on blood pressure." | 1.31 | Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. ( Brown, NJ; Donnert, E; Fogo, AB; Freeman, M; Ma, L; Nakamura, I; Nakamura, S; Vaughan, DE, 2000) |
| "Infarct healing and left ventricular remodeling were evaluated at 3, 7, and 28 days after MI by determination of the diastolic pressure-volume relationship of the left ventricle, the infarct-thinning ratio, and the collagen-volume fraction." | 1.31 | Effect of a selective aldosterone receptor antagonist in myocardial infarction. ( Delyani, JA; Robinson, EL; Rudolph, AE, 2001) |
| "Among the determinants of cardiac failure, the renin-angiotensin-aldosterone system has a central role, and antagonism of the mineralocorticoid receptor (MR) has been proposed as a therapeutic strategy." | 1.31 | Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. ( Beggah, AT; Bocchi, B; Cailmail, S; Delage, V; Delcayre, C; Escoubet, B; Farman, N; Jaisser, F; Ouvrard-Pascaud, A; Peuchmaur, M; Puttini, S, 2002) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 1.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 1.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension." | 1.28 | Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (3.80) | 18.2507 |
| 2000's | 74 (46.84) | 29.6817 |
| 2010's | 67 (42.41) | 24.3611 |
| 2020's | 11 (6.96) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, J | 1 |
| Jablonowski, R | 1 |
| Mohammad, M | 1 |
| Solem, K | 1 |
| Borgquist, R | 1 |
| Ostenfeld, E | 1 |
| Arheden, H | 1 |
| Carlsson, M | 1 |
| Leader, CJ | 2 |
| Wilkins, GT | 2 |
| Walker, RJ | 2 |
| Reddy, YNV | 1 |
| Sundaram, V | 1 |
| Chang, WT | 1 |
| Lin, YW | 1 |
| Chen, CY | 1 |
| Chen, ZC | 1 |
| Shih, JY | 1 |
| Wu, CC | 1 |
| Luo, CY | 1 |
| Liu, PY | 1 |
| Yadin, D | 1 |
| Guetta, T | 1 |
| Petrover, Z | 1 |
| Alcalai, R | 1 |
| Seidman, J | 1 |
| Seidman, CE | 1 |
| Ofek, E | 1 |
| Kornowski, R | 1 |
| Hochhauser, E | 1 |
| Arad, M | 1 |
| Chen, Y | 1 |
| Yu, Y | 1 |
| Qiao, J | 1 |
| Zhu, L | 1 |
| Xiao, Z | 1 |
| Pellicori, P | 2 |
| Ferreira, JP | 3 |
| Mariottoni, B | 2 |
| Brunner-La Rocca, HP | 1 |
| Ahmed, FZ | 2 |
| Verdonschot, J | 1 |
| Collier, T | 1 |
| Cuthbert, JJ | 1 |
| Petutschnigg, J | 2 |
| Mujaj, B | 2 |
| Girerd, N | 2 |
| González, A | 3 |
| Clark, AL | 2 |
| Cosmi, F | 2 |
| Staessen, JA | 2 |
| Heymans, S | 2 |
| Latini, R | 2 |
| Rossignol, P | 5 |
| Zannad, F | 6 |
| Cleland, JGF | 2 |
| Gorshunova, NK | 1 |
| Savich, VV | 1 |
| Kelly, DJ | 1 |
| Sammut, IA | 1 |
| Cuthbert, J | 1 |
| Verdonschot, JAJ | 1 |
| Brunner La Rocca, HP | 1 |
| Mamas, MA | 1 |
| Edelmann, F | 2 |
| Pieske, B | 3 |
| Khan, J | 1 |
| McDonald, K | 1 |
| Rouet, P | 1 |
| Diez, J | 3 |
| Hazebroek, M | 1 |
| Grojean, S | 1 |
| Pizard, A | 1 |
| Collier, TJ | 1 |
| Pitt, B | 2 |
| Byrd, JB | 1 |
| Kisheva, A | 1 |
| Yotov, Y | 1 |
| Chervenkov, T | 1 |
| Angelov, A | 1 |
| Bocheva, Y | 1 |
| Wang, CH | 1 |
| Wang, Z | 3 |
| Liang, LJ | 1 |
| Wang, XT | 1 |
| Ma, XL | 1 |
| Liu, BB | 1 |
| He, JQ | 1 |
| Shimosawa, T | 1 |
| Xu, QY | 1 |
| Arumugam, S | 1 |
| Sreedhar, R | 1 |
| Karuppagounder, V | 1 |
| Harima, M | 1 |
| Nakamura, M | 1 |
| Suzuki, H | 2 |
| Sone, H | 1 |
| Watanabe, K | 2 |
| Donderski, R | 1 |
| Stróżecki, P | 1 |
| Sulikowska, B | 1 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 1 |
| Kawasaki, M | 1 |
| Yamada, T | 1 |
| Okuyama, Y | 1 |
| Morita, T | 1 |
| Furukawa, Y | 1 |
| Tamaki, S | 1 |
| Iwasaki, Y | 1 |
| Kikuchi, A | 1 |
| Sakata, Y | 2 |
| Fukunami, M | 1 |
| Slavic, S | 1 |
| Ford, K | 1 |
| Modert, M | 1 |
| Becirovic, A | 1 |
| Handschuh, S | 1 |
| Baierl, A | 1 |
| Katica, N | 1 |
| Zeitz, U | 1 |
| Erben, RG | 1 |
| Andrukhova, O | 1 |
| Hori, Y | 2 |
| Touei, D | 1 |
| Saitoh, R | 1 |
| Yamagishi, M | 2 |
| Kanai, K | 2 |
| Hoshi, F | 2 |
| Itoh, N | 2 |
| Elseweidy, MM | 1 |
| Askar, ME | 1 |
| Elswefy, SE | 1 |
| Shawky, M | 1 |
| Takemoto, Y | 1 |
| Ramirez, RJ | 1 |
| Kaur, K | 1 |
| Salvador-Montañés, O | 1 |
| Ponce-Balbuena, D | 1 |
| Ramos-Mondragón, R | 1 |
| Ennis, SR | 1 |
| Guerrero-Serna, G | 1 |
| Berenfeld, O | 1 |
| Jalife, J | 1 |
| Kim, SK | 1 |
| McCurley, AT | 1 |
| DuPont, JJ | 1 |
| Aronovitz, M | 1 |
| Moss, ME | 1 |
| Stillman, IE | 1 |
| Karumanchi, SA | 1 |
| Christou, DD | 1 |
| Jaffe, IZ | 3 |
| Maron, MS | 1 |
| Chan, RH | 1 |
| Kapur, NK | 1 |
| McGraw, AP | 1 |
| Kerur, R | 1 |
| Maron, BJ | 1 |
| Udelson, JE | 1 |
| Ravassa, S | 1 |
| Trippel, T | 1 |
| Bach, D | 1 |
| Bachran, D | 1 |
| López, B | 1 |
| Wachter, R | 1 |
| Hasenfuss, G | 1 |
| Delles, C | 1 |
| Dominiczak, AF | 1 |
| Koszegi, S | 1 |
| Molnar, A | 1 |
| Lenart, L | 1 |
| Hodrea, J | 1 |
| Balogh, DB | 1 |
| Lakat, T | 1 |
| Szkibinszkij, E | 1 |
| Hosszu, A | 1 |
| Sparding, N | 1 |
| Genovese, F | 1 |
| Wagner, L | 1 |
| Vannay, A | 1 |
| Szabo, AJ | 1 |
| Fekete, A | 1 |
| Chen, X | 2 |
| Ge, W | 1 |
| Dong, T | 1 |
| Hu, J | 1 |
| Chen, L | 1 |
| Fan, X | 1 |
| Gong, Y | 1 |
| Zhou, H | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Nielsen, FT | 1 |
| Jensen, BL | 1 |
| Hansen, PB | 1 |
| Marcussen, N | 1 |
| Bie, P | 1 |
| Preston, IR | 1 |
| Sagliani, KD | 1 |
| Warburton, RR | 1 |
| Hill, NS | 1 |
| Fanburg, BL | 1 |
| Esposito, CT | 1 |
| Varahan, S | 1 |
| Jeyaraj, D | 1 |
| Lu, Y | 1 |
| Stambler, BS | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Iwase, E | 1 |
| Takahashi, K | 1 |
| Ohtake, M | 2 |
| Tsuboi, K | 1 |
| Miyachi, M | 1 |
| Murohara, T | 2 |
| Nagata, K | 2 |
| Zanotti, S | 1 |
| Gibertini, S | 1 |
| Savadori, P | 1 |
| Mantegazza, R | 1 |
| Mora, M | 1 |
| Dos, L | 1 |
| Pujadas, S | 1 |
| Estruch, M | 1 |
| Mas, A | 1 |
| Ferreira-González, I | 1 |
| Pijuan, A | 1 |
| Serra, R | 1 |
| Ordóñez-Llanos, J | 1 |
| Subirana, M | 1 |
| Pons-Lladó, G | 1 |
| Marsal, JR | 1 |
| García-Dorado, D | 1 |
| Casaldàliga, J | 1 |
| Wong, KY | 1 |
| Wong, SY | 1 |
| McSwiggan, S | 1 |
| Ogston, SA | 1 |
| Sze, KY | 1 |
| MacWalter, RS | 1 |
| Struthers, AD | 3 |
| De Mello, WC | 1 |
| Leung, M | 1 |
| Wong, VW | 1 |
| Heritier, S | 1 |
| Mihailidou, AS | 1 |
| Leung, DY | 1 |
| Tomaschitz, A | 1 |
| Ritz, E | 1 |
| Rus-Machan, J | 1 |
| Kienreich, K | 1 |
| Verheyen, N | 1 |
| Gaksch, M | 1 |
| Grübler, M | 1 |
| Fahrleitner-Pammer, A | 1 |
| Mrak, P | 1 |
| Toplak, H | 1 |
| Kraigher-Krainer, E | 1 |
| März, W | 1 |
| Pilz, S | 1 |
| Ramírez, E | 1 |
| Klett-Mingo, M | 1 |
| Ares-Carrasco, S | 1 |
| Picatoste, B | 1 |
| Ferrarini, A | 1 |
| Rupérez, FJ | 1 |
| Caro-Vadillo, A | 1 |
| Barbas, C | 1 |
| Egido, J | 2 |
| Tuñón, J | 1 |
| Lorenzo, Ó | 1 |
| Chen, H | 1 |
| Sun, F | 1 |
| Zhong, X | 1 |
| Shao, Y | 1 |
| Yoshimura, A | 1 |
| Liu, Y | 3 |
| Lavall, D | 1 |
| Selzer, C | 1 |
| Schuster, P | 1 |
| Lenski, M | 1 |
| Adam, O | 1 |
| Schäfers, HJ | 1 |
| Böhm, M | 1 |
| Laufs, U | 1 |
| Coelho-Filho, OR | 1 |
| Shah, RV | 1 |
| Neilan, TG | 1 |
| Mitchell, R | 1 |
| Moreno, H | 1 |
| Kwong, R | 1 |
| Jerosch-Herold, M | 1 |
| Sun, QL | 1 |
| Li, M | 1 |
| Rui, HL | 1 |
| Chen, YP | 1 |
| Kiehl, EL | 1 |
| Shivapour, DM | 1 |
| Goenka, AH | 1 |
| Jaber, WA | 1 |
| Jeewandara, TM | 1 |
| Ameer, OZ | 1 |
| Boyd, R | 1 |
| Wyse, BF | 1 |
| Underwood, CF | 1 |
| Phillips, JK | 1 |
| Bostick, B | 1 |
| Habibi, J | 2 |
| DeMarco, VG | 1 |
| Jia, G | 1 |
| Domeier, TL | 1 |
| Lambert, MD | 1 |
| Aroor, AR | 1 |
| Nistala, R | 1 |
| Bender, SB | 1 |
| Garro, M | 1 |
| Hayden, MR | 2 |
| Ma, L | 2 |
| Manrique, C | 1 |
| Sowers, JR | 2 |
| Rodansky, ES | 1 |
| Johnson, LA | 2 |
| Huang, S | 1 |
| Spence, JR | 1 |
| Higgins, PD | 2 |
| Fedorova, OV | 1 |
| Emelianov, IV | 1 |
| Bagrov, KA | 1 |
| Grigorova, YN | 1 |
| Wei, W | 1 |
| Juhasz, O | 1 |
| Frolova, EV | 1 |
| Marshall, CA | 1 |
| Lakatta, EG | 1 |
| Konradi, AO | 1 |
| Bagrov, AY | 1 |
| Cezar, MD | 1 |
| Damatto, RL | 1 |
| Pagan, LU | 1 |
| Lima, AR | 1 |
| Martinez, PF | 1 |
| Bonomo, C | 1 |
| Rosa, CM | 1 |
| Campos, DH | 1 |
| Cicogna, AC | 1 |
| Gomes, MJ | 1 |
| Oliveira, SA | 1 |
| Blotta, DA | 1 |
| Okoshi, MP | 1 |
| Okoshi, K | 1 |
| Martínez-Martínez, E | 1 |
| Calvier, L | 1 |
| Fernández-Celis, A | 1 |
| Rousseau, E | 1 |
| Jurado-López, R | 1 |
| Rossoni, LV | 2 |
| Jaisser, F | 2 |
| Cachofeiro, V | 4 |
| López-Andrés, N | 2 |
| Zhao, H | 1 |
| Gu, DW | 1 |
| Li, HT | 1 |
| Ge, QF | 1 |
| Li, GP | 1 |
| Martín-Fernández, B | 4 |
| Rubio-Navarro, A | 1 |
| Cortegano, I | 1 |
| Ballesteros, S | 3 |
| Alía, M | 1 |
| Cannata-Ortiz, P | 1 |
| Olivares-Álvaro, E | 1 |
| de Andrés, B | 1 |
| Gaspar, ML | 1 |
| de Las Heras, N | 3 |
| Lahera, V | 4 |
| Moreno, JA | 1 |
| Liu, G | 1 |
| Wang, R | 1 |
| Hou, T | 1 |
| Chen, C | 1 |
| Zheng, S | 1 |
| Dong, Z | 1 |
| Condorelli, G | 1 |
| Jotti, GS | 1 |
| Pagiatakis, C | 1 |
| Zhang, W | 1 |
| Wang, Q | 1 |
| Du, L | 1 |
| Yi, Y | 1 |
| Liu, X | 2 |
| Duan, S | 1 |
| Tanino, A | 1 |
| Okura, T | 2 |
| Nagao, T | 2 |
| Kukida, M | 1 |
| Pei, Z | 1 |
| Enomoto, D | 2 |
| Miyoshi, K | 2 |
| Okamura, H | 1 |
| Higaki, J | 2 |
| Sánchez-Más, J | 1 |
| Lax, A | 1 |
| Asensio-López, MC | 1 |
| Fernández-Del Palacio, MJ | 1 |
| Caballero, L | 1 |
| Navarro-Peñalver, M | 1 |
| Pérez-Martínez, MT | 1 |
| Gimeno-Blanes, JR | 1 |
| Pascual-Figal, DA | 1 |
| Richardson, RV | 1 |
| Batchen, EJ | 1 |
| Thomson, AJ | 1 |
| Darroch, R | 1 |
| Pan, X | 1 |
| Rog-Zielinska, EA | 1 |
| Wyrzykowska, W | 1 |
| Scullion, K | 1 |
| Al-Dujaili, EA | 1 |
| Diaz, ME | 1 |
| Moran, CM | 1 |
| Kenyon, CJ | 1 |
| Gray, GA | 1 |
| Chapman, KE | 1 |
| Taira, M | 1 |
| Toba, H | 1 |
| Murakami, M | 1 |
| Iga, I | 1 |
| Serizawa, R | 1 |
| Murata, S | 1 |
| Kobara, M | 2 |
| Nakata, T | 1 |
| Ikeda, H | 1 |
| Tsuruya, K | 1 |
| Toyonaga, J | 1 |
| Masutani, K | 1 |
| Hayashida, H | 1 |
| Hirakata, H | 1 |
| Iida, M | 2 |
| Cavallari, LH | 2 |
| Fashingbauer, LA | 1 |
| Camp, JR | 2 |
| King, ST | 1 |
| Geenen, DL | 1 |
| Xu, G | 1 |
| Liu, A | 1 |
| Lea, WB | 1 |
| Kwak, ES | 1 |
| Luther, JM | 2 |
| Fowler, SM | 1 |
| Ma, J | 1 |
| Fogo, AB | 3 |
| Brown, NJ | 3 |
| van den Borne, SW | 1 |
| Isobe, S | 2 |
| Zandbergen, HR | 1 |
| Li, P | 1 |
| Petrov, A | 1 |
| Wong, ND | 1 |
| Fujimoto, S | 1 |
| Fujimoto, A | 1 |
| Lovhaug, D | 1 |
| Smits, JF | 1 |
| Daemen, MJ | 1 |
| Blankesteijn, WM | 1 |
| Reutelingsperger, C | 1 |
| Narula, N | 1 |
| Vannan, MA | 1 |
| Hofstra, L | 1 |
| Narula, J | 1 |
| Jansen, PM | 1 |
| Danser, AH | 1 |
| Imholz, BP | 1 |
| van den Meiracker, AH | 1 |
| Du, J | 1 |
| Fan, YY | 1 |
| Hitomi, H | 1 |
| Kiyomoto, H | 1 |
| Kimura, S | 2 |
| Kong, CZ | 1 |
| Noma, T | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 2 |
| Nakano, D | 1 |
| Shafiq, MM | 1 |
| Miller, AB | 1 |
| Pellman, J | 1 |
| Lyon, RC | 1 |
| Sheikh, F | 1 |
| Bauer, R | 1 |
| Blain, A | 1 |
| Greally, E | 1 |
| Lochmüller, H | 1 |
| Bushby, K | 1 |
| MacGowan, GA | 1 |
| Straub, V | 1 |
| Guney, I | 1 |
| Selcuk, NY | 1 |
| Altintepe, L | 1 |
| Atalay, H | 1 |
| Başarali, MK | 1 |
| Büyükbaş, S | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Goto, K | 1 |
| Otsubo, T | 1 |
| Kanashiro-Takeuchi, RM | 1 |
| Heidecker, B | 1 |
| Lamirault, G | 1 |
| Dharamsi, JW | 1 |
| Hare, JM | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Miana, M | 2 |
| Delgado, C | 1 |
| Song, S | 1 |
| Hintze, T | 1 |
| Yoshioka, K | 1 |
| Higuchi, S | 1 |
| Ito, M | 1 |
| Tomita, M | 1 |
| Hoyano, M | 1 |
| Obata, H | 1 |
| Ding, L | 1 |
| Chinushi, M | 1 |
| Hanawa, H | 1 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Williams, RS | 1 |
| deLemos, JA | 1 |
| Dimas, V | 1 |
| Reisch, J | 1 |
| Hill, JA | 1 |
| Naseem, RH | 1 |
| Brem, AS | 1 |
| Morris, DJ | 1 |
| Gong, R | 1 |
| Irita, J | 1 |
| Jotoku, M | 1 |
| Kurata, M | 1 |
| Desilva, VR | 1 |
| Matsui, Y | 2 |
| Uede, T | 2 |
| Denhardt, DT | 1 |
| Rittiling, SR | 1 |
| Fortuno, MA | 1 |
| Iwazu, Y | 2 |
| Muto, S | 4 |
| Hirahara, I | 1 |
| Fujisawa, G | 4 |
| Takeda, S | 1 |
| Kusano, E | 4 |
| Govani, SM | 1 |
| Joyce, JC | 1 |
| Waljee, AK | 1 |
| Gillespie, BW | 1 |
| Kosmala, W | 2 |
| Przewlocka-Kosmala, M | 2 |
| Szczepanik-Osadnik, H | 2 |
| Mysiak, A | 2 |
| O'Moore-Sullivan, T | 1 |
| Marwick, TH | 2 |
| Wu, SY | 1 |
| Yu, YR | 1 |
| Cai, Y | 1 |
| Jia, LX | 1 |
| Wang, X | 1 |
| Xiao, CS | 1 |
| Tang, CS | 1 |
| Qi, YF | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Davel, AP | 1 |
| Azibani, F | 1 |
| Benard, L | 1 |
| Schlossarek, S | 1 |
| Merval, R | 1 |
| Tournoux, F | 1 |
| Fazal, L | 1 |
| Polidano, E | 1 |
| Launay, JM | 1 |
| Carrier, L | 1 |
| Chatziantoniou, C | 1 |
| Samuel, JL | 1 |
| Delcayre, C | 5 |
| Luo, P | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Parlakgumus, A | 1 |
| Colakoglu, T | 1 |
| Kayaselcuk, F | 1 |
| Colakoglu, S | 1 |
| Ezer, A | 1 |
| Calıskan, K | 1 |
| Karakaya, J | 1 |
| Yildirim, S | 1 |
| Lim, YS | 1 |
| Han, JS | 1 |
| Kim, KA | 1 |
| Yoon, JH | 1 |
| Kim, CY | 1 |
| Lee, HS | 1 |
| Sun, Y | 2 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Weber, KT | 4 |
| Funder, JW | 5 |
| Fritsch Neves, M | 1 |
| Schiffrin, EL | 3 |
| Young, MJ | 2 |
| Moussa, L | 1 |
| Dilley, R | 1 |
| Okada, K | 4 |
| Fujita, N | 2 |
| Itabashi, N | 2 |
| Ishibashi, S | 3 |
| Lal, A | 2 |
| Veinot, JP | 2 |
| Leenen, FH | 2 |
| Blasi, ER | 1 |
| Rocha, R | 2 |
| Rudolph, AE | 3 |
| Blomme, EA | 2 |
| Polly, ML | 1 |
| McMahon, EG | 2 |
| Kambara, A | 1 |
| Holycross, BJ | 1 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 1 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Qin, W | 1 |
| Bond, BR | 1 |
| Goellner, JJ | 1 |
| Tsybouleva, N | 1 |
| Zhang, L | 1 |
| Chen, S | 1 |
| Patel, R | 1 |
| Lutucuta, S | 1 |
| Nemoto, S | 1 |
| DeFreitas, G | 1 |
| Entman, M | 1 |
| Carabello, BA | 1 |
| Roberts, R | 1 |
| Marian, AJ | 1 |
| Young, M | 2 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Endemann, DH | 1 |
| Touyz, RM | 1 |
| Iglarz, M | 1 |
| Savoia, C | 1 |
| Jia, N | 1 |
| Okamoto, H | 1 |
| Kon, S | 1 |
| Onozuka, H | 1 |
| Akino, M | 1 |
| Liu, L | 1 |
| Morimoto, J | 1 |
| Rittling, SR | 1 |
| Denhardt, D | 1 |
| Kitabatake, A | 1 |
| Miyamori, I | 2 |
| Khan, NU | 1 |
| Movahed, A | 1 |
| Trachtman, H | 1 |
| Weiser, AC | 1 |
| Valderrama, E | 1 |
| Morgado, M | 1 |
| Palmer, LS | 1 |
| Wahed, MI | 1 |
| Ma, M | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 2 |
| Tachikawa, H | 1 |
| Kuster, GM | 1 |
| Kotlyar, E | 1 |
| Rude, MK | 1 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Colucci, WS | 1 |
| Sam, F | 1 |
| Yamamoto, T | 1 |
| Yano, M | 1 |
| Asai, M | 1 |
| Monkawa, T | 1 |
| Marumo, T | 1 |
| Fukuda, S | 1 |
| Tsuji, M | 1 |
| Yoshino, J | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Ganten, D | 1 |
| Nehme, JA | 1 |
| Lacolley, P | 4 |
| Labat, C | 3 |
| Challande, P | 1 |
| Robidel, E | 2 |
| Perret, C | 1 |
| Leenhardt, A | 2 |
| Safar, ME | 4 |
| Milliez, P | 2 |
| Wakabayashi, K | 1 |
| Sato, T | 1 |
| Iso, Y | 1 |
| Katagiri, T | 1 |
| Takeyama, Y | 1 |
| Deangelis, N | 1 |
| Rucker-Martin, C | 1 |
| Vicaut, E | 1 |
| Beaufils, P | 1 |
| Hatem, SN | 1 |
| Nattel, S | 1 |
| Nishikawa, N | 1 |
| Yamamoto, K | 1 |
| Mano, T | 1 |
| Yoshida, J | 1 |
| Umekawa, S | 1 |
| Hori, M | 2 |
| Yasuhara, Y | 1 |
| Sonoyama, T | 1 |
| Harada, A | 1 |
| Masuyama, T | 1 |
| Roongsritong, C | 1 |
| Sutthiwan, P | 1 |
| Bradley, J | 1 |
| Simoni, J | 1 |
| Power, S | 1 |
| Meyerrose, GE | 1 |
| Izawa, H | 1 |
| Asano, H | 1 |
| Amano, T | 1 |
| Ichihara, S | 1 |
| Kato, T | 1 |
| Ohshima, S | 1 |
| Murase, Y | 1 |
| Iino, S | 1 |
| Obata, K | 1 |
| Noda, A | 1 |
| Okumura, K | 1 |
| Yokota, M | 1 |
| Neves, MF | 1 |
| Amiri, F | 1 |
| Virdis, A | 1 |
| Diep, QN | 1 |
| Abe, Y | 2 |
| Vallon, V | 1 |
| Wyatt, AW | 1 |
| Klingel, K | 1 |
| Huang, DY | 1 |
| Hussain, A | 1 |
| Berchtold, S | 1 |
| Friedrich, B | 1 |
| Grahammer, F | 1 |
| Belaiba, RS | 1 |
| Görlach, A | 1 |
| Wulff, P | 1 |
| Daut, J | 1 |
| Dalton, ND | 1 |
| Ross, J | 1 |
| Flögel, U | 1 |
| Schrader, J | 1 |
| Osswald, H | 1 |
| Kandolf, R | 1 |
| Kuhl, D | 1 |
| Lang, F | 1 |
| Nagase, M | 1 |
| Shibata, S | 1 |
| Yoshida, S | 1 |
| Nagase, T | 1 |
| Gotoda, T | 1 |
| Fujita, T | 1 |
| Tsukamoto, O | 1 |
| Minamino, T | 1 |
| Sanada, S | 1 |
| Hirata, A | 1 |
| Fujita, M | 1 |
| Shintani, Y | 1 |
| Yulin, L | 1 |
| Asano, Y | 1 |
| Takashima, S | 1 |
| Yamasaki, S | 1 |
| Tomoike, H | 1 |
| Kitakaze, M | 1 |
| Pérez-Rojas, J | 1 |
| Blanco, JA | 1 |
| Cruz, C | 1 |
| Trujillo, J | 1 |
| Vaidya, VS | 1 |
| Uribe, N | 1 |
| Bonventre, JV | 1 |
| Gamba, G | 1 |
| Bobadilla, NA | 1 |
| Kawai, Y | 1 |
| Fan, CY | 1 |
| Susic, D | 1 |
| Varagic, J | 1 |
| Ahn, J | 1 |
| Matavelli, L | 1 |
| Frohlich, ED | 1 |
| Gullulu, M | 1 |
| Akdag, I | 1 |
| Kahvecioglu, S | 1 |
| Filiz, G | 1 |
| Savci, V | 1 |
| Epstein, M | 2 |
| Nehme, J | 1 |
| Mercier, N | 1 |
| Benetos, A | 3 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Hwang, HS | 1 |
| Cirrincione, G | 1 |
| Thomas, DP | 1 |
| McCormick, RJ | 1 |
| Boluyt, MO | 1 |
| Stas, S | 1 |
| Whaley-Connell, A | 1 |
| Appesh, L | 1 |
| Karuparthi, PR | 1 |
| Qazi, M | 1 |
| Morris, EM | 1 |
| Cooper, SA | 1 |
| Link, CD | 1 |
| Stump, C | 1 |
| Hay, M | 1 |
| Ferrario, C | 1 |
| Nishioka, T | 1 |
| Suzuki, M | 1 |
| Onishi, K | 1 |
| Takakura, N | 1 |
| Inada, H | 1 |
| Yoshida, T | 1 |
| Hiroe, M | 1 |
| Imanaka-Yoshida, K | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Stamos, TD | 1 |
| Takeda, M | 1 |
| Tatsumi, T | 1 |
| Matsunaga, S | 1 |
| Hayashi, H | 1 |
| Kimata, M | 1 |
| Honsho, S | 1 |
| Nishikawa, S | 1 |
| Mano, A | 1 |
| Shiraishi, J | 1 |
| Yamada, H | 1 |
| Matoba, S | 1 |
| Matsubara, H | 1 |
| Thomas, M | 1 |
| Vidal, A | 1 |
| Bhattacharya, SK | 1 |
| Ahokas, RA | 1 |
| Gerling, IC | 1 |
| Rickard, AJ | 1 |
| Morgan, J | 1 |
| Fuller, PJ | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Yoneda, T | 1 |
| Usukura, M | 1 |
| Takata, H | 1 |
| Nakazawa, E | 1 |
| Nishimura, H | 1 |
| Ito, Y | 1 |
| Mizuno, M | 1 |
| Tanaka, A | 1 |
| Morita, Y | 1 |
| Maruyama, S | 1 |
| Yuzawa, Y | 1 |
| Matsuo, S | 1 |
| Paulis, L | 1 |
| Matuskova, J | 1 |
| Adamcova, M | 1 |
| Pelouch, V | 1 |
| Simko, J | 1 |
| Krajcirovicova, K | 1 |
| Potacova, A | 1 |
| Hulin, I | 1 |
| Janega, P | 1 |
| Pechanova, O | 1 |
| Simko, F | 1 |
| Head, G | 1 |
| Funder, J | 1 |
| Nicoletti, A | 1 |
| Heudes, D | 1 |
| Hinglais, N | 1 |
| Appay, MD | 1 |
| Philippe, M | 1 |
| Sassy-Prigent, C | 1 |
| Bariety, J | 1 |
| Michel, JB | 1 |
| Brilla, CG | 3 |
| Matsubara, LS | 1 |
| MacFadyen, RJ | 1 |
| Barr, CS | 1 |
| Nakamura, S | 1 |
| Nakamura, I | 1 |
| Donnert, E | 1 |
| Freeman, M | 1 |
| Vaughan, DE | 1 |
| Lucet, B | 1 |
| Ledudal, K | 1 |
| Miric, G | 1 |
| Dallemagne, C | 1 |
| Endre, Z | 1 |
| Margolin, S | 1 |
| Taylor, SM | 1 |
| Brown, L | 1 |
| Delyani, JA | 1 |
| Robinson, EL | 1 |
| De Feo, S | 1 |
| Opasich, C | 1 |
| Volpi, A | 1 |
| Tavazzi, L | 1 |
| Beggah, AT | 1 |
| Escoubet, B | 1 |
| Puttini, S | 1 |
| Cailmail, S | 1 |
| Delage, V | 1 |
| Ouvrard-Pascaud, A | 1 |
| Bocchi, B | 1 |
| Peuchmaur, M | 1 |
| Farman, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study[NCT04190420] | 310 participants (Anticipated) | Observational | 2018-10-01 | Enrolling by invitation | |||
| Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.[NCT00703352] | Phase 4 | 26 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial[NCT03049540] | Phase 3 | 100 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [NCT00005757] | 293 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
18 reviews available for spironolactone and Fibrosis
| Article | Year |
|---|---|
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Bone Density; Bone Diseases; Calcium; Cardiovascular Diseases; | 2014 |
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Extracellular Matrix; Fibrosi | 2010 |
Aldosterone-induced fibrosis in the kidney: questions and controversies.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Antihypertensive Agents; Blood Pressure; Child, | 2011 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
Aldosterone: a risk factor for vascular disease.
Topics: Aldosterone; Animals; Arteries; Fibrosis; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoi | 2003 |
[Involvement of Aldosterone and mineralocorticoid receptor in pathogenesis of cardiovascular diseases].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Angiotensin II; Cardiovascular Diseases; F | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; My | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular | 2004 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibrobl | 2006 |
[Cardiovascular action of aldosterone].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Sodium Channels; Ep | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib | 2006 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Aldosterone as a determinant of cardiovascular and renal dysfunction.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Endothelium, Vascular; Fibrosis; Huma | 2001 |
[The process of drug development. The "case" of spironolactone].
Topics: Animals; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin | 2002 |
16 trials available for spironolactone and Fibrosis
| Article | Year |
|---|---|
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; N | 2020 |
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Topics: Aged; Aging; Biomarkers; Female; Fibrosis; Heart Failure; Humans; Male; Peptide Fragments; Procollag | 2021 |
Galectin-3 in patients with atrial fibrillation and restored sinus rhythm.
Topics: Aged; Atrial Fibrillation; Biomarkers; Female; Fibrosis; Galectin 3; Gout; Humans; Kidney Diseases; | 2021 |
Eplerenone might affect atrial fibrosis in patients with hypertension.
Topics: Aged; Atrial Fibrillation; Electrocardiography; Eplerenone; Female; Fibrosis; Heart Atria; Humans; H | 2017 |
Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
Topics: Adult; Biomarkers; Cardiomyopathy, Hypertrophic; Collagen Type I; Double-Blind Method; Fibrosis; Hea | 2018 |
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Topics: Aged; Biomarkers; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Double-Bl | 2018 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial.
Topics: Aged; Amiloride; Cross-Over Studies; Diuretics; Double-Blind Method; Female; Fibrosis; Heart Disease | 2013 |
Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Ag | 2013 |
Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
Topics: Adrenergic Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Female | 2009 |
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2011 |
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Topics: Body Mass Index; Double-Blind Method; Echocardiography, Doppler; Female; Fibrosis; Follow-Up Studies | 2013 |
Spironolactone improves diastolic function in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Coronary Artery Disease; Diastole; Double-Blind Method; Fem | 2005 |
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Biopsy; Cardiomyopathy, Dilated; Female; Fibrosis; Heart Failure; Humans; Male; Middle | 2005 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Circadian Rhythm; Diuretics; Double-Blin | 1997 |
124 other studies available for spironolactone and Fibrosis
| Article | Year |
|---|---|
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail | 2021 |
The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat.
Topics: Animals; Antifibrotic Agents; Cytochrome P-450 CYP1A1; Disease Progression; Fibrosis; Heart; Hyperte | 2021 |
Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Topics: Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2022 |
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Genetic Therapy; Glycogen Storage Disease Type IIb; | 2023 |
Mineralocorticoid receptor excessive activation involved in glucocorticoid-related brain injury.
Topics: Animals; Apoptosis; Atrophy; Blood Pressure; Brain Injuries; Dexamethasone; Fibrosis; Glucocorticoid | 2020 |
[Features of fibrosis and disorders of the collagen metabolism of the interstitial matrix of the myocardium in patients with arterial hypertension and possibilities of their correction with sartname.]
Topics: Aged; Case-Control Studies; Collagen; Female; Fibrosis; Heart; Humans; Hypertension; Myocardium; Spi | 2019 |
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Hypertension; Kidney Disease | 2020 |
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
Topics: Aging; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; ras Proteins; Spiron | 2021 |
The Inhibitory Effect of Eplerenone on Cell Proliferation in the Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction.
Topics: Actins; Aldosterone; Animals; Cell Proliferation; Collagen; Eplerenone; Fibrosis; Immediate-Early Pr | 2017 |
Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.
Topics: Animals; Autoimmunity; Biomarkers; Cardiac Myosins; Cardiomyopathy, Dilated; Disease Models, Animal; | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc | 2017 |
The Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left Ventricle.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-Agonists; Animals; Cells, Cultured; Col | 2017 |
Nephrotoxicity Induced by Cisplatin Intake in Experimental Rats and Therapeutic Approach of Using Mesenchymal Stem Cells and Spironolactone.
Topics: Allografts; Animals; Cisplatin; Fibrosis; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal S | 2018 |
Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Cardiac Pacing, Artificial; Eplerenone; Fibrosis; M | 2017 |
Smooth Muscle Cell-Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging.
Topics: Aged; Animals; Cellular Senescence; Disease Progression; Exercise Tolerance; Fibrosis; Gene Expressi | 2018 |
Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
Topics: Biomarkers; Fibrosis; Heart Failure; Humans; Spironolactone; Stroke Volume | 2018 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin | 2019 |
Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats.
Topics: Animals; Cardio-Renal Syndrome; Cells, Cultured; Epithelial-Mesenchymal Transition; Fibrosis; Human | 2019 |
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Drug Interactions; Eplerenone; Fibrosis; Immunosuppressive Agents; Kidney; Lo | 2013 |
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
Topics: Aldosterone; Animals; Arterial Pressure; Body Weight; Cardiac Output; Cell Proliferation; Fibrosis; | 2013 |
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Topics: Animals; Atrophy; Blood Pressure; Corticosterone; Disease Models, Animal; Fibrosis; Heart Diseases; | 2013 |
Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents.
Topics: Biological Assay; Blotting, Western; Collagen; Decorin; Drug Evaluation, Preclinical; Enzyme-Linked | 2013 |
Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR(mRen2)27 rats.
Topics: Amides; Animals; Blood Pressure; Coronary Vessels; Echocardiography; Fibrosis; Fumarates; Heart; Hea | 2015 |
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; D | 2013 |
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Eplerenone; Fibrosis; Inflammation; Male; Miner | 2013 |
The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Atrial Fibrillation; Connective Tissue Growth | 2014 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 2014 |
Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.
Topics: Animals; Cardiac Imaging Techniques; Cardiomegaly; Fibrosis; Heart; Hypertension; Magnetic Resonance | 2014 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas | 2015 |
Male breast uptake in rubidium-82 PET due to spironolactone-induced gynecomastia.
Topics: Aged, 80 and over; Breast; Breast Neoplasms, Male; Diagnosis, Differential; Fibrosis; Gynecomastia; | 2015 |
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
Topics: Animals; Aorta; Biomarkers; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progress | 2015 |
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
Topics: Animals; Cardiomegaly; Diastole; Diet, High-Fat; Diet, Western; Dietary Sucrose; Disease Models, Ani | 2015 |
Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs.
Topics: Actins; Calcium-Binding Proteins; Cell Differentiation; Cells, Cultured; Collagen Type I; Collagen T | 2015 |
Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
Topics: Animals; Aorta; Arterial Pressure; Bufanolides; Canrenone; Cells, Cultured; Collagen Type I; Endothe | 2015 |
Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats.
Topics: Animals; Fibrosis; Heart; Heart Failure; Hypertension; Male; Mineralocorticoid Receptor Antagonists; | 2015 |
Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Hyperal | 2015 |
Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats.
Topics: Animals; Blotting, Western; Cell Count; Collagen; Fibrosis; Male; Microscopy, Polarization; Myocardi | 2015 |
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco | 2016 |
Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
Topics: Action Potentials; Animals; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Collagen; Cytoprotection; | 2016 |
Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?
Topics: Cardiomyopathies; Fibroblasts; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonis | 2016 |
Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice.
Topics: Animals; Blotting, Western; Cells, Cultured; Coculture Techniques; Connective Tissue Growth Factor; | 2016 |
Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice.
Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Humans; Interleukin-18; Kidney; Kidney Diseases; Mal | 2016 |
The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction.
Topics: Actinin; Animals; Atrial Natriuretic Factor; Blotting, Western; Eplerenone; Fibrosis; Gene Expressio | 2016 |
Glucocorticoid receptor alters isovolumetric contraction and restrains cardiac fibrosis.
Topics: Animals; Corticosterone; Female; Fibrosis; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myo | 2017 |
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Topics: Animals; Collagen Type I; Collagen Type IV; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Experimenta | 2008 |
Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.
Topics: Animals; Fibrosis; Hemodynamics; Inflammation; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; | 2009 |
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen Type I; Fibrosis; Gene Expression Regula | 2008 |
Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.
Topics: Actins; Aldosterone; Butadienes; Cadherins; Cell Transdifferentiation; Cells, Cultured; Collagen; En | 2008 |
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Topics: Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Enzyme Inhibitors; Fibrosis; Heart Diseases; Kidn | 2009 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2009 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism.
Topics: Administration, Oral; Animals; Body Weight; Fibrosis; Glucocorticoids; Heart; Heart Diseases; Hemody | 2010 |
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Blood Pressure; Eplerenone; Fib | 2010 |
Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
Topics: Animals; Cluster Analysis; Eplerenone; Female; Fibrosis; Gene Expression Profiling; Gene Expression | 2009 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression.
Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Heart; Immediate-Early Proteins; Interleukin-1; Male | 2011 |
Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats.
Topics: Animals; Fibrosis; Gene Expression Regulation, Enzymologic; Heart Diseases; Isoproterenol; Male; Mat | 2011 |
Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
Topics: Animals; Atrial Fibrillation; Cardiomegaly; Eplerenone; Fibrosis; Heart Atria; Hypertension; Male; M | 2011 |
Effect of spironolactone on patients with atrial fibrillation and structural heart disease.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Elect | 2011 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; | 2011 |
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal | 2011 |
Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats.
Topics: Animals; Collagen; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Drug Therapy, | 2011 |
Spironolactone and colitis: increased mortality in rodents and in humans.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Colitis; Crohn Disease; Female; Fibrosis; | 2012 |
Endogenous aldosterone is involved in vascular calcification in rat.
Topics: Aldosterone; Alkaline Phosphatase; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Topics: Aldosterone; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blo | 2012 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; | 2013 |
Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites.
Topics: Diuretics; Drug Therapy, Combination; Female; Fibrosis; Furosemide; Humans; Kidney Tubules; Male; Mi | 2002 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Blood Pressure; Carbenoxolone; Cardiomegaly; Coronar | 2003 |
Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
Topics: Animals; Blood Pressure; Cardiomegaly; Collagen; Desoxycorticosterone; Fibrosis; Guanidines; Male; M | 2003 |
Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Diuretics; Dose-Response Relationship, | 2003 |
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Cytokines; Eplerenone; Fibrosis; Hypertension, Renal; Immunohi | 2003 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats.
Topics: Animals; Biomarkers; Coronary Vessels; Desoxycorticosterone; Eplerenone; Fibrosis; Male; Mineralocor | 2004 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone | 2004 |
Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction.
Topics: Animals; Fibrosis; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; S | 2004 |
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Immunohisto | 2004 |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship | 2005 |
Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Topics: Animals; Aorta; Apoptosis; Blood Pressure; Cell Size; Chronic Disease; Constriction, Pathologic; Dru | 2005 |
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Blood Pressure; Cilazapri | 2004 |
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins | 2005 |
Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure.
Topics: Animals; Carotid Arteries; Compliance; Drug Therapy, Combination; Echocardiography; Elasticity; Fibr | 2005 |
Eplerenone suppresses neointimal formation after coronary stent implantation in swine.
Topics: Actins; Administration, Oral; Animals; Blood Vessel Prosthesis Implantation; Collagen Type I; Collag | 2006 |
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M | 2005 |
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Failure; Mineralocorticoid Re | 2005 |
Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy.
Topics: Adult; Aged; Animals; Echocardiography, Doppler; Female; Fibrosis; Heart Ventricles; Humans; Hypertr | 2005 |
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Collagen; Ectodysplasins; Fibrosis; Heart; Hypertension | 2005 |
SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.
Topics: Angiotensins; Animals; Blood Pressure; Connective Tissue Growth Factor; Desoxycorticosterone; Fibros | 2006 |
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segm | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination | 2006 |
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyc | 2007 |
Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR.
Topics: Animals; Blood Pressure; Coronary Circulation; Eplerenone; Fibrosis; Hypertension; Male; Mineralocor | 2007 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Prolife | 2006 |
Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone.
Topics: Animals; Aorta; Blood Pressure; Blotting, Northern; Carotid Artery Diseases; Collagen; Eplerenone; F | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis.
Topics: Aging; Aldosterone; Animals; Atrial Natriuretic Factor; Collagen; Collagen Type III; Female; Fibrosi | 2007 |
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Topics: Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Chronic Disease; Fibrosis; Mag | 2007 |
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines; | 2007 |
Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Apoptosis; Blood Pressure; Cells, Cultured; Fi | 2007 |
Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone.
Topics: Aldosterone; Animals; Coronary Vessels; Disease Models, Animal; Feces; Fibrosis; Homeostasis; Hypera | 2007 |
Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
Topics: Animals; Biomarkers; Blood Pressure; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Desoxycortico | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis.
Topics: Animals; Apoptosis; Capillaries; Connective Tissue Growth Factor; Desoxycorticosterone; Endothelium, | 2008 |
Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model.
Topics: Animals; Blood Pressure; Blotting, Western; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Fi | 2008 |
Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone.
Topics: Animals; Aorta; Arginine; Fibrosis; Hypertension; Hypertrophy, Left Ventricular; Male; Mineralocorti | 2008 |
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.
Topics: Adrenalectomy; Aldosterone; Animals; Desoxycorticosterone; Drug Combinations; Fibrosis; Fludrocortis | 1995 |
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen | 1995 |
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Hyperaldosteronism; Hypertension; | 1993 |
Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Collagen; Fibrosis; Heart Rate; Hypertension; Isoquinoline | 1997 |
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blotting, Northern; Creatinine; Disease Progre | 2000 |
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
Topics: Age Factors; Aldosterone; Animals; Aorta; Carotid Arteries; Endomyocardial Fibrosis; Fibrosis; Hemod | 2001 |
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calci | 2001 |
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
Topics: Animals; Eplerenone; Fibrosis; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; | 2001 |
Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.
Topics: Animals; Base Sequence; Disease Models, Animal; DNA, Complementary; Fibrosis; Gene Expression; Heart | 2002 |
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype | 1992 |